<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107145</url>
  </required_header>
  <id_info>
    <org_study_id>PAACT-PV</org_study_id>
    <nct_id>NCT01107145</nct_id>
  </id_info>
  <brief_title>Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)</brief_title>
  <acronym>PAACT-PV</acronym>
  <official_title>A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current treatment recommendations for P. vivax in pregnant and non-pregnant individuals
      are to use chloroquine; in non-pregnant patients this is followed by primaquine to prevent
      relapse. As primaquine can not be used in pregnant women, these women remain at risk of
      relapse. As there is increasing concern about chloroquine resistant P. vivax in this region,
      there is a need to identify alternative treatment options. The artemisinin combination
      therapies are recommended for use against P. falciparum infections in pregnant women after
      the 1st trimester; additional data are needed to support the use of these drugs against P.
      vivax.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Extremely slow enrollment
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>63-day PCR-adjusted parasitological cure of P. vivax</measure>
    <time_frame>63 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Plasmodium Vivax Malaria</condition>
  <arm_group>
    <arm_group_label>Mefloquine- Artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine- Artesunate</intervention_name>
    <description>Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.</description>
    <arm_group_label>Mefloquine- Artesunate</arm_group_label>
    <other_name>Artesunato-Mefloquina (Farmaguinhos, Brazil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine</intervention_name>
    <description>4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal</description>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
    <other_name>Coartem, Novartis</other_name>
    <other_name>Lumet, Cipla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <other_name>Chloroquine (Farmaguinhos, Brazil)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age &gt;16 weeks (determined by LMP and fundal height)- if there is
             discordance between the two, the more conservative estimate (i.e. lower) will be used,
             to prevent accidental exposure of a 1st trimester fetus

          -  Normal fetal heart beat detected by Doppler

          -  Presence of asexual P. vivax parasitemia â‰¤ 50,000 parasites/microliter (thick smear)

          -  Willing to sign or thumb print informed consent

          -  Willing to return for scheduled follow up visits for treatment and observation until
             delivery

          -  Willing to deliver in health facility

        Exclusion Criteria:

          -  Pregnancy &lt; 16 weeks

          -  Microscopically confirmed P. falciparum or mixed infection/ parasitemia (P. vivax and
             another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae)

          -  History of allergy or hypersensitivity to interventional drugs

          -  Exposure to antimalarial drugs and other drugs with antimalarial activity within the
             past 2 months, as determined by history from the woman (quinine, mefloquine, or
             artemisinin derivatives, including AL and MA)

          -  Patients taking drugs with possible interaction with study drugs (ie. warfarin,
             digoxin)

          -  History or family history of epilepsy or psychiatric disorder

          -  Presence of signs and symptoms of severe malaria, severe illness, or danger signs

          -  Hemoglobin &lt; 7 g/dl

          -  Inability to tolerate oral medication (repeated vomiting, impairment of
             consciousness).

          -  History of chronic disease including diabetes, renal failure, hepatic failure, heart
             disease requiring anti-arrhythmic drugs or warfarin, HIV/ AIDS, known hemoglobinopathy

          -  Participant's inability to return for follow up visits

          -  Age &lt;15 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meghna Desai, MPH PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Geral Maternidade de Cruzeiro do Sul</name>
      <address>
        <city>Cruzeiro do Sul</city>
        <state>Acre</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Municipal Teonila Alves</name>
      <address>
        <city>Anajas</city>
        <state>Para</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa em Patologias Tropicais</name>
      <address>
        <city>Porto Velho</city>
        <state>Rondonia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium</keyword>
  <keyword>Vivax</keyword>
  <keyword>Malaria</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Brazil</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Mefloquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

